TY - JOUR
T1 - Anticancer therapy targeting the apoptotic pathway
AU - Hu, Wei
AU - Kavanagh, John J.
PY - 2003/12
Y1 - 2003/12
N2 - Apoptosis, or programmed cell death, has an essential role in controlling cell number in many developmental and physiological settings and in chemotherapy-induced tumour-cell killing. It is a genetically regulated biological process, guided by the ratio of proapoptotic and anti-apoptotic proteins. Recently, inducers of apoptosis have been used in cancer therapy. Several studies have attempted to induce apoptosis by triggering the tumour-necrosis-factor-related apoptosis-inducing ligand receptor and the BCL2 family of proteins, and others have targeted the caspases, and proteins that inhibit apoptosis. Most of these therapies are still in preclinical development because of their low efficacy and susceptibility to drug resistance, but some of them have shown promising results. In this article, we review the development and clinical efficacy of proapoptotic drugs that have shown promise.
AB - Apoptosis, or programmed cell death, has an essential role in controlling cell number in many developmental and physiological settings and in chemotherapy-induced tumour-cell killing. It is a genetically regulated biological process, guided by the ratio of proapoptotic and anti-apoptotic proteins. Recently, inducers of apoptosis have been used in cancer therapy. Several studies have attempted to induce apoptosis by triggering the tumour-necrosis-factor-related apoptosis-inducing ligand receptor and the BCL2 family of proteins, and others have targeted the caspases, and proteins that inhibit apoptosis. Most of these therapies are still in preclinical development because of their low efficacy and susceptibility to drug resistance, but some of them have shown promising results. In this article, we review the development and clinical efficacy of proapoptotic drugs that have shown promise.
UR - http://www.scopus.com/inward/record.url?scp=0346873049&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0346873049&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(03)01277-4
DO - 10.1016/S1470-2045(03)01277-4
M3 - Review article
C2 - 14662428
AN - SCOPUS:0346873049
SN - 1470-2045
VL - 4
SP - 721
EP - 729
JO - Lancet Oncology
JF - Lancet Oncology
IS - 12
ER -